Neptune to Hold Conference Call to Discuss Fourth Quarter and Fiscal Year-End Results for the Thirteen Months Period Ended March 31, 2017
LAVAL, QUEBEC--(Marketwired - May 18, 2017) - Neptune Technologies & Bioressources Inc. ("Neptune" or the "Company") (NEPT.TO)(NEPT.TO), announces that it will be holding a conference call on June 7, 2017 at 5:00 PM (EST) to discuss its fourth quarter and fiscal year-end results for the thirteen months period ended March 31, 2017.
The fourth quarter results press release will be issued on the same day at 4:00 PM (EST).
Conference Call Details:
Date: | Wednesday, June 7, 2017 |
Time: | 5:00 PM Eastern Standard Time |
Call: | 1 (877) 223-4471 (within Canada and the U.S.) |
Webcast: | A live audio webcast and presentation of the results can be accessed at: |
A replay of the call will be available for replay two hours after the call's completion, until July 7, 2017. The telephone numbers to access the replay of the call are 1 (416) 621-4642 or 1 (800) 585-8367 (toll-free), Conference ID 23766321. The archive of the webcast, along with its accompanying presentation, will also be made available immediately in the Investors section of Neptune's website under Investor Events and Presentations.
About Neptune Technologies & Bioressources Inc.
Neptune is a nutrition products company focused on the business of customized unique nutrition solutions, specialty ingredients and consumer brands. The company develops turnkey solutions available in various unique delivery forms. Neptune also offers premium krill oil manufactured in its state-of-the art facility and a variety of other specialty ingredients such as marine and seed oils. Neptune sells its premium krill oil under the OCEANO3® brand directly to consumers in Canada and the United States through web sales at www.oceano3.com. OCEANO3 is also sold as a turnkey solution to distributors. The Company's head office is located in Laval, Quebec.
Neptune is also pursuing opportunities in the prescription drug markets, through its approximately 34% owned subsidiary Acasti Pharma Inc. ("Acasti"). Acasti focuses on the research, development and commercialization of new krill oil-based forms of omega-3 phospholipid therapies for the treatment of severe hypertriglyceridemia.
SOURCE: Neptune Technologies & Bioressources Inc.
